Group 1 - The core point of the article highlights that Sai Sheng Pharmaceutical experienced a stock price increase of 6.39%, closing at 12.16 yuan, with a significant block trade occurring [1] - The block trade involved a total volume of 820,000 shares and a transaction amount of 8.774 million yuan, with the first transaction price at 10.70 yuan, reflecting a premium rate of -12.01% [1] - The buyer was China Galaxy Securities Co., Ltd., and the seller was Industrial Securities Co., Ltd., indicating active trading interest in the stock [1] Group 2 - Over the past three months, the stock has recorded one block trade with a total transaction amount of 8.774 million yuan [1] - In the last five trading days, the stock has seen a cumulative increase of 9.06%, with a net inflow of 20.991 million yuan from major funds [1]

Core Viewpoint - The company, Sai Sheng Pharmaceutical (300485.SZ), has received a notification from Ms. Ma Li regarding her share reduction progress, indicating a planned decrease in her holdings in the company [1] Group 1 - Ms. Ma Li reduced her shareholding by a total of 3.3282 million shares [1] - The reduction represents 0.69% of the company's total share capital [1] - The share reduction occurred between November 18, 2025, and January 13, 2026, through centralized bidding and block trading methods [1]

证券代码：300485 证券简称：赛升药业 公告编号：2026-001 北京赛升药业股份有限公司 关于公司控股股东、实际控制人及一致行动人股份权益 变动触及 1%整数倍的公告 | 1.基本情况 | | | --- | --- | | 信息披露义务人 马丽 | | | 住所 | 北京市海淀区*** | | 2025 年 权益变动时间 | 11 月 18 日-2026 年 1 月 13 日 | | 权益变动过程 | 马丽女士因个人资金需求，于 2025 年 11 月 18 日-2026 年 1 月 | | 13 | 日通过集中竞价和大宗交易方式累计减持公司股份 332.82 | | | | | 司控股股东、实际控制人及一致行动人股份持有公司股份的比 | | | | --- | --- | --- | --- | --- | --- | | | | | 万股，占公司现有总股本比例为 | | 0.69%，本次减持股份后，公 | | | | 例由 57.52%减少至 | 56.83%。权益变动触及 | 1%整数倍。 | | | 股票简称 | 赛升药业 | | 股票代码 | 300485 | | | 变动方向 | 上升□ ...

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical (300485) has reported a total of 33,621 shareholders as of December 31, 2025 [1]

Group 1 - The Shanghai Composite Index is at 4005.73 points, above the annual line, with an increase of 0.93% [1] - The total trading volume of A-shares today is 1,402.986 billion yuan [1] - A total of 154 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates including Yingkang Life, Gangtong Medical, and Beilu Pharmaceutical at 10.63%, 10.61%, and 9.97% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Yingkang Life (12.85% increase, 10.63% deviation) - Gangtong Medical (11.91% increase, 10.61% deviation) - Beilu Pharmaceutical (10.20% increase, 9.97% deviation) [1] - Other notable stocks with significant increases include: - Guanhao Biological (14.87% increase, 8.29% deviation) - Baichu Electronics (6.95% increase, 6.79% deviation) [1] - Stocks with smaller deviation rates that have just crossed the annual line include *ST Yedao, Shiyan Institute, and Shanxi Securities [1]

Group 1 - The core point of the article is that Saiseng Pharmaceutical has announced the approval of a financial assistance extension to its subsidiary Junyuan Pharmaceutical by its fifth board of directors' twelfth meeting [2] Group 2 - The financial assistance is aimed at supporting the operations of Junyuan Pharmaceutical [2] - The decision reflects the company's strategy to ensure the stability and growth of its subsidiary [2] - This move may indicate the company's commitment to maintaining its investment in the pharmaceutical sector [2]

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical announced a board meeting to discuss financial support for its subsidiary, Junyuan Pharmaceutical, and provided details on its revenue composition for 2024 [1] - Sai Sheng Pharmaceutical's revenue for the year 2024 is primarily derived from the pharmaceutical manufacturing sector, accounting for 99.63% of total revenue, while other businesses contribute only 0.37% [1] - As of the report, Sai Sheng Pharmaceutical has a market capitalization of 5.2 billion yuan [1] Group 2 - The article also highlights a significant event involving Moutai's distributor conference, where over 2,000 attendees gathered to discuss major changes related to Moutai's pricing and distribution strategies [1] - Chairman Chen Hua emphasized that distributors can no longer rely on passive income, indicating a shift in the business model [1]

证券代码：300485 证券简称：赛升药业 公告编号：2025-053 北京赛升药业股份有限公司 关于向子公司君元药业提供财务资助展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、北京赛升药业股份有限公司（以下简称"公司"）拟对子公司沈阳君元 药业有限公司（以下简称"子公司"或"君元药业"）提供的财务资助进行展期， 借款期限延长至 2028 年 12 月 28 日，按年利率 3%结算利息。 本次财务资助展期事项不影响公司正常业务开展及资金使用，不属于深交所 《创业板股票上市规则》《创业板规范运作指引》等规定的不得提供财务资助的 情形。 （二）审议情况 本次财务资助展期事项已经公司第五届董事会独立董事专门会议 2025 年第 四次会议、第五届董事会第十二次会议审议通过，无需提交股东会审议。 二、被资助对象的基本情况 （一）基本情况 2、本次财务资助展期事项已经公司第五届董事会独立董事专门会议 2025 年第四次会议、第五届董事会第十二次会议审议通过，无需提交公司股东会审议。 3、本次财务资助展期对象为公司合并报表范围内的子公司，公司 ...

北京赛升药业股份有限公司 第五届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 证券代码：300485 证券简称：赛升药业 公告编号：2025-052 二、会议审议情况 经全体董事认真审议并表决，会议通过了以下议案： 北京赛升药业股份有限公司（以下简称"公司"）第五届董事会第十二次会 议于2025年12月26日在公司会议室召开，本次会议于2025年12月22日以通讯的方 式向所有董事送达了会议通知。应参与会议董事9名，实际参会董事9人，会议由 董事长马骉主持，公司高级管理人员列席了本次会议。本次会议的召开符合《中 华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公司 章程》的规定，会议决议合法、有效。 北京赛升药业股份有限公司 经审议，董事会认为：本次公司向君元药业提供财务资助的展期，是基于对 君元药业的认可及后续发展的信心，为进一步支持君元药业的日常经营和业务发 展，符合公司的发展战略。本次财务资助展期是公司在不影响自身正常经营的前 提下进行的，风险处于可控制范围内，不会对公司的正常运作和日常经 ...

Group 1 - The biopharmaceutical sector increased by 0.18% on December 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] - Key stocks in the biopharmaceutical sector showed various performance, with Jindike (688670) rising by 4.66% to a closing price of 22.45 [1] Group 2 - The biopharmaceutical sector experienced a net outflow of 307 million yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2] - Notable declines included Te Bao Biological (688278), which fell by 3.14% to a closing price of 80.90 [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Wan Ze Co. (000534) achieving a turnover of 488 million yuan [1][2] Group 3 - Jindike (688670) had a net inflow of 25.23 million yuan from institutional investors, while retail investors had a net outflow of 23.95 million yuan [3] - Other stocks like Zhi Xiang Jin Tai (688443) and Shen Zhou Cell (688520) also showed mixed net inflows and outflows from different investor categories [3] - The overall trend indicates a divergence in investor sentiment, with institutional investors pulling back while retail investors increased their positions [2][3]